Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
San-Huang-Xie-Xin-Tang is a traditional Chinese medicine (TCM) formula used for centuries for gastrointestinal and inflammatory disorders, including gastritis, gastric bleeding, peptic ulcers, atherosclerosis, upper respiratory tract infection, diabetic nephropathy, and more[1][2][7]. The formula comprises three herbs: Coptidis rhizoma (Coptis chinensis), Rhei rhizoma (Rheum palmatum or Rheum officinale), and Scutellariae radix (Scutellaria baicalensis)[1][2][3][4][5]. Its mechanism is largely anti-inflammatory and immunomodulatory, related to suppression of cytokine/chemokine production, inhibition of the NF-κB pathway, and reduction of MAPK signaling. It also possesses anti-oxidant, anti-hypertensive, neuroprotective, and anti-apoptotic effects[1][2][7]. Active constituents include berberine, baicalin, emodin, rhein, aloe-emodin, and baicalein[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on san-huang-xie-xin-tang.